Article Detail - JA DME

Effective October 1, 2024, Capecitabine with dates of service October 1, 2024, through January 6, 2025, shall be billed with HCPCS code J8999 (prescription drug, oral, chemotherapeutic, NOS). Suppliers shall utilize HCPCS J8999 and include drug name "Capecitabine" in the claim narrative until the January 2025 release and implementation of the new cross-walked HCPCS code J8522. Suppliers are currently billing for Capecitabine oral anti-cancer drugs to the Durable Medical Equipment Medicare Administrative Contactors (DME MACs) using the associated NDC. HCPCS Codes J8520 and J8521 will be removed from the policy. There are no changes to the policy requirements for Capecitabine.